## Wilson I Gonsalves

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/904912/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood, 2017, 129, 2111-2119.	1.4	249
2	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	6.2	171
3	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute, 2014, 106, .	6.3	140
4	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	3.0	115
5	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	1.4	111
6	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
7	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. Journal of Clinical Oncology, 2018, 36, 1323-1329.	1.6	100
8	Effects of Volume and Site of Blood Draw on Blood Culture Results. Journal of Clinical Microbiology, 2009, 47, 3482-3485.	3.9	97
9	The New Oral Anticoagulants in Clinical Practice. Mayo Clinic Proceedings, 2013, 88, 495-511.	3.0	93
10	Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity. Cell Reports, 2018, 22, 1365-1373.	6.4	85
11	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. British Journal of Haematology, 2014, 167, 500-505.	2.5	81
12	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	2.4	81
13	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
14	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology, 2017, 92, 668-673.	4.1	75
15	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	3.0	72
16	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia, 2019, 33, 531-536.	7.2	72
17	Nâ€terminal fragment of the typeâ€B natriuretic peptide (NTâ€proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	4.1	71
18	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71

#	Article	IF	CITATIONS
19	Effect of Palliative Care Services on the Aggressiveness of End-of-Life Care in the Veteran's Affairs Cancer Population. Journal of Palliative Medicine, 2011, 14, 1231-1235.	1.1	70
20	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	7.2	64
21	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	6.2	64
22	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	6.2	62
23	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing. Mayo Clinic Proceedings, 2019, 94, 472-483.	3.0	59
24	Longâ€ŧerm outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	4.1	57
25	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57
26	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	1.4	54
27	Combination therapy incorporating Bclâ $\in 2$ inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). European Journal of Haematology, 2018, 100, 215-217.	2.2	52
28	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	1.4	50
29	Efficacy of VDT PACEâ€like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	4.1	49
30	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1037-1046.	4.5	46
31	Induction therapy preâ€autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	4.1	45
32	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine, 2017, 49, 545-551.	3.8	45
33	Systemic Immunoglobulin Light Chain Amyloidosis–Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	3.0	43
34	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May HarborMYD88L265P Mutations. American Journal of Clinical Pathology, 2016, 145, 843-851.	0.7	43
35	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	7.2	43
36	Betaâ€blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	4.1	41

#	Article	IF	CITATIONS
37	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41
38	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
39	Tenâ€year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	2.5	40
40	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	7.2	40
41	Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. JCI Insight, 2018, 3, .	5.0	39
42	Association Between Race and Survival of Patients With Non–Small-Cell Lung Cancer in the United States Veterans Affairs Population. Clinical Lung Cancer, 2014, 15, 152-158.	2.6	38
43	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.4	38
44	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
45	Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	4.1	37
46	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology, 2019, 94, 1020-1026.	4.1	36
47	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	7.2	36
48	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal, 2020, 10, 55.	6.2	36
49	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	4.1	35
50	Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology, 2011, 78, 227-242.	4.4	33
51	Impact of MYD88 <sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
52	Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. Clinical Lung Cancer, 2021, 22, 67-70.	2.6	33
53	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	3.0	32
54	Continued improvement in survival in multiple myeloma (MM) including high-risk patients Journal of Clinical Oncology, 2019, 37, 8039-8039.	1.6	31

#	Article	IF	CITATIONS
55	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	6.2	29
56	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	7.2	29
57	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28
58	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Advances, 2019, 3, 744-750.	5.2	28
59	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	7.2	28
60	Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effect. Nature Metabolism, 2021, 3, 954-968.	11.9	28
61	Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. Haematologica, 2019, 104, 2061-2074.	3.5	27
62	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	7.2	27
63	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal, 2020, 10, 20.	6.2	26
64	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1284-1289.	0.7	25
65	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ⁻ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
66	Efficacy of daratumumabâ€based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	4.1	25
67	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	3.0	25
68	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, 50.	6.2	25
69	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). Blood, 2014, 124, 304-304.	1.4	25
70	Sarcoidosis Presenting with Pancytopenia. American Journal of Medicine, 2014, 127, e9-e10.	1.5	24
71	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 447-452.	0.4	24
72	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. American Journal of Hematology, 2017, 92, 549-554.	4.1	24

#	Article	IF	CITATIONS
73	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	4.1	24
74	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	5.2	23
75	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	5.2	23
76	Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer — A Veterans Affairs Cancer Registry analysis. Journal of Geriatric Oncology, 2011, 2, 209-214.	1.0	22
77	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research, 2016, 44, 32-39.	0.8	22
78	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	7.2	22
79	Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood, 2013, 122, 1746-1749.	1.4	21
80	Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis. Blood, 2017, 130, 1578-1584.	1.4	21
81	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	2.0	21
82	Implications of detecting serum monoclonal protein by MASSâ€ <b>f</b> ix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	2.5	21
83	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology, 2021, 96, 1131-1136.	4.1	21
84	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia, 2018, 32, 1414-1420.	7.2	20
85	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2019, 25, e108-e111.	2.0	20
86	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia, 2019, 33, 730-738.	7.2	20
87	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. British Journal of Haematology, 2019, 184, 1014-1017.	2.5	20
88	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	5.2	20
89	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 101-108.	4.1	19
90	Utility and prognostic value of <sup>18</sup> Fâ€FDG positron emission tomographyâ€computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	4.1	19

#	Article	IF	CITATIONS
91	Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. Scientific Reports, 2020, 10, 10250.	3.3	19
92	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. Vascular Medicine, 2017, 22, 121-127.	1.5	18
93	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 306-311.	4.1	18
94	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	6.2	18
95	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	6.2	18
96	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. British Journal of Haematology, 2019, 185, 701-707.	2.5	17
97	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. American Journal of Hematology, 2019, 94, E141-E143.	4.1	17
98	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	4.1	17
99	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. American Journal of Hematology, 2017, 92, 435-440.	4.1	16
100	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Mayo Clinic Proceedings, 2018, 93, 56-58.	3.0	16
101	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer Journal, 2018, 8, 106.	6.2	16
102	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Advances, 2020, 4, 5425-5430.	5.2	16
103	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	3.0	16
104	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 455-464.	3.0	16
105	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	2.5	15
106	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. British Journal of Haematology, 2018, 182, 71-77.	2.5	15
107	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	4.1	15
108	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	7.2	15

#	Article	IF	CITATIONS
109	In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer & Metabolism, 2020, 8, 29.	5.0	15
110	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.4	15
111	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150.	2.4	15
112	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2960-2960.	1.4	15
113	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	4.1	14
114	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14
115	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology, 2019, 94, 1066-1071.	4.1	14
116	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	4.1	14
117	Impact of belantamab mafodotinâ€induced ocular toxicity on outcomes of patients with advanced multiple myeloma. British Journal of Haematology, 2022, 199, 95-99.	2.5	14
118	Granulomatous Inflammation Detected by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in Patients With a Concurrent Diagnosis of Cancer. Journal of Bronchology and Interventional Pulmonology, 2012, 19, 176-181.	1.4	13
119	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone ( <scp>VRd</scp> ) as firstâ€line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	4.1	13
120	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Advances, 2021, 5, 2753-2759.	5.2	13
121	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 864-864.	1.4	13
122	Substratification of patients with newly diagnosed standardâ€risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	2.5	12
123	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia, 2019, 33, 1273-1277.	7.2	12
124	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	6.2	12
125	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	4.1	12
126	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	4.1	12

#	Article	IF	CITATIONS
127	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	3.0	12
128	Assessment of fixedâ€duration therapies for treatmentâ€naÃ⁻ve <scp>Waldenström</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12
129	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
130	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	7.2	12
131	The use of novel agents in multiple myeloma patients with hepatic impairment. Future Oncology, 2015, 11, 501-510.	2.4	11
132	The next generation of novel therapies for the management of relapsed multiple myeloma. Future Oncology, 2017, 13, 63-75.	2.4	11
133	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology, 2018, 93, 17-22.	4.1	11
134	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	4.1	11
135	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	2.5	10
136	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.	3.5	10
137	Crystalglobulin-Induced Nephropathy and Keratopathy. Kidney Medicine, 2019, 1, 71-74.	2.0	10
138	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. American Journal of Hematology, 2020, 95, E8-E10.	4.1	10
139	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	1.4	10
140	Visual Loss in Early-Stage Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2013, 31, e280-e282.	1.6	9
141	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 587-594.	2.4	9
142	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	3.0	9
143	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2039-2050.	2.4	9
144	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation, 2019, 25, 1520-1525.	2.0	9

#	Article	IF	CITATIONS
145	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. Bone Marrow Transplantation, 2019, 54, 1775-1779.	2.4	9
146	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	5.2	9
147	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.4	9
148	Early Mortality in Multiple Myeloma: Risk Factors and Impact on Population Outcomes. Blood, 2014, 124, 1320-1320.	1.4	9
149	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	7.2	8
150	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
151	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.4	8
152	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	2.4	8
153	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	6.2	8
154	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances, 2020, 4, 322-326.	5.2	8
155	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	7.2	8
156	Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort. American Journal of Hematology, 2021, 96, 446-454.	4.1	8
157	Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study Journal of Clinical Oncology, 2019, 37, 7559-7559.	1.6	8
158	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	6.2	8
159	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	1.4	8
160	Melflufen for multiple myeloma: a promise unfulfilled?. Lancet Haematology,the, 2022, 9, e82-e84.	4.6	8
161	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100. Leukemia, 2022, 36, 1429-1431.	7.2	8
162	Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S147.	0.4	7

#	Article	IF	CITATIONS
163	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.	2.4	7
164	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Advances, 2019, 3, 1226-1229.	5.2	7
165	Characteristics of longâ€ŧerm survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer, 2019, 125, 3574-3581.	4.1	7
166	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia, 2019, 33, 1268-1272.	7.2	7
167	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081.	2.4	7
168	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	7.2	7
169	Estimating the annual volume of hematologic cancer cases per hematologist–oncologist in the United States: are we treating rare cancers too rarely?. Leukemia and Lymphoma, 2017, 58, 251-252.	1.3	6
170	Second Autologous Hematopoietic Stem Cell Transplant as Salvage Therapy for Relapsed Multiple Myeloma: A Global Treatment Option for Eligible Patients. Acta Haematologica, 2018, 139, 45-46.	1.4	6
171	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplantation and Cellular Therapy, 2021, 27, 770.e1-770.e7.	1.2	6
172	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	4.1	6
173	Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma. American Journal of Hematology, 2022, , .	4.1	6
174	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	4.1	5
175	Defining Lymphoplasmacytic Lymphoma. American Journal of Clinical Pathology, 2018, 150, 168-176.	0.7	5
176	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	2.4	5
177	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	2.4	5
178	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 355-360.	0.4	5
179	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. Cancer Treatment and Research Communications, 2021, 29, 100444.	1.7	5
180	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.	1.4	5

#	Article	IF	CITATIONS
181	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. Blood, 2016, 128, 3337-3337.	1.4	5
182	Supportive care in multiple myeloma: Current practices and advances. Cancer Treatment and Research Communications, 2021, 29, 100476.	1.7	5
183	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	4.1	5
184	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	4.1	5
185	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 40-41.	3.0	4
186	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	3.0	4
187	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	2.4	4
188	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2960-2967.	1.3	4
189	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	4.1	4
190	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1402-1405.	2.0	4
191	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	2.2	4
192	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. Blood, 2020, 136, 52-53.	1.4	4
193	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 36-37.	1.4	4
194	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	1.4	4
195	PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma. Blood, 2014, 124, 3382-3382.	1.4	4
196	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	1.4	4
197	Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM) Journal of Clinical Oncology, 2019, 37, 7509-7509.	1.6	4
198	Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Blood, 2019, 134, 3160-3160.	1.4	4

#	Article	IF	CITATIONS
199	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. Blood, 2019, 134, 1697-1697.	1.4	4
200	Epstein-Barr Virus Infection in an Elderly Nonimmunocompromised Adult Successfully Treated with Rituximab. Case Reports in Hematology, 2014, 2014, 1-4.	0.4	3
201	Effect of Surgical Intervention on Survival of Patients With Clinical N2 Non–Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 142-146.	1.3	3
202	Serum free light chain measurements to reduce 24â€h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	4.1	3
203	Colon perforation in multiple myeloma patients – A complication of highâ€dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	2.8	3
204	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	6.2	3
205	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	2.2	3
206	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy, 2021, 27, 589.e1-589.e6.	1.2	3
207	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	1.4	3
208	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	1.4	3
209	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM) Journal of Clinical Oncology, 2016, 34, 8004-8004.	1.6	3
210	What are patients' biggest concerns? A patient reported outcome case-management system Journal of Clinical Oncology, 2017, 35, 6572-6572.	1.6	3
211	Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. Oncotarget, 2018, 9, 34582-34594.	1.8	3
212	Characteristics and outcome of patients with MYD88 wild-type Waldenström Macroglobulinemia Journal of Clinical Oncology, 2020, 38, 8550-8550.	1.6	3
213	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. Blood, 2021, 138, 1639-1639.	1.4	3
214	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	7.2	3
215	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	6.2	3
216	Chronic Eosinophilic Leukemia—Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma. Case Reports in Hematology, 2013, 2013, 1-4.	0.4	2

#	Article	IF	CITATIONS
217	Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL). Biology of Blood and Marrow Transplantation, 2019, 25, S30.	2.0	2
218	Predictors of short-term survival in Waldenström Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	1.3	2
219	Reductive amination of α-Ketoglutarate in metabolite extracts results in glutamate overestimation. Journal of Chromatography A, 2020, 1623, 461169.	3.7	2
220	Of lions, shar-pei, and doughnuts: a tale retold. Blood, 2020, 135, 1074-1076.	1.4	2
221	Ageism in the t(11;14) Subtype of Multiple Myeloma. Acta Haematologica, 2021, 144, 6-7.	1.4	2
222	Outcomes of multiple myeloma patients with <scp>del 17p</scp> undergoing autologous stem cell transplantation. American Journal of Hematology, 2021, 96, E35-E38.	4.1	2
223	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	1.3	2
224	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. Leukemia Research Reports, 2021, 15, 100242.	0.4	2
225	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	1.3	2
226	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. Blood, 2019, 134, 4386-4386.	1.4	2
227	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2019, 134, 1905-1905.	1.4	2
228	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. Blood, 2020, 136, 48-49.	1.4	2
229	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	1.4	2
230	Daratumumab-based therapies in patients with AL amyloidosis Journal of Clinical Oncology, 2018, 36, 8053-8053.	1.6	2
231	Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome Journal of Clinical Oncology, 2019, 37, 8019-8019.	1.6	2
232	Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience Journal of Clinical Oncology, 2019, 37, e19519-e19519.	1.6	2
233	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	1.4	2
234	Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) Journal of Clinical Oncology, 2019, 37, 8031-8031.	1.6	2

#	Article	IF	CITATIONS
235	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. Blood, 2021, 138, 2711-2711.	1.4	2
236	Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2021, 138, 2735-2735.	1.4	2
237	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). Blood, 2020, 136, 29-30.	1.4	2
238	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2022, 63, 2422-2427.	1.3	2
239	Gallbladder cancer-associated thrombotic microangiopathy. Future Oncology, 2013, 9, 1711-1715.	2.4	1
240	POEMS syndrome: An elusive diagnosis. American Journal of Hematology, 2017, 92, 1269-1270.	4.1	1
241	Outcomes of Autologous Hematopoietic Stem Cell Transplant in Sporadic Late Onset Nemaline Myopathy with Associated Monoclonal Gammopathy of Unknown Significance. Biology of Blood and Marrow Transplantation, 2018, 24, S124-S125.	2.0	1
242	59-Year-Old Man With Fatigue, Weight Loss, and Hepatomegaly. Mayo Clinic Proceedings, 2018, 93, 1525-1529.	3.0	1
243	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. Bone Marrow Transplantation, 2019, 54, 1898-1907.	2.4	1
244	Venetoclax For The Treatment of Translocation AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e332.	0.4	1
245	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a â€~graft versus host'-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	2.4	1
246	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	2.4	1
247	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 309.e1-309.e5.	1.2	1
248	Practical management and assessment of primary plasma cell leukemia in the novel agent era. Cancer Treatment and Research Communications, 2021, 28, 100414.	1.7	1
249	Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience Journal of Clinical Oncology, 2021, 39, e20000-e20000.	1.6	1
250	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	1.4	1
251	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. Blood, 2019, 134, 4334-4334.	1.4	1
252	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	1.4	1

#	Article	IF	CITATIONS
253	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. Blood, 2020, 136, 22-23.	1.4	1
254	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	1.4	1
255	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	1.4	1
256	Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base. Blood, 2016, 128, 3249-3249.	1.4	1
257	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	1.4	1
258	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. Blood, 2016, 128, 3444-3444.	1.4	1
259	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.	1.4	1
260	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression Journal of Clinical Oncology, 2016, 34, 8015-8015.	1.6	1
261	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM) Journal of Clinical Oncology, 2017, 35, 8038-8038.	1.6	1
262	Factors predicting organ response in light chain amyloidosis (AL) Journal of Clinical Oncology, 2017, 35, 8048-8048.	1.6	1
263	Improvement in Renal Function and Its Impact on Survival in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 3368-3368.	1.4	1
264	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naÃ⁻ve (TN) Waldenström macroglobulinemia (WM) Journal of Clinical Oncology, 2016, 34, 7552-7552.	1.6	1
265	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. Blood, 2016, 128, 5918-5918.	1.4	1
266	Natural history of t(11;14) multiple myeloma (MM) Journal of Clinical Oncology, 2017, 35, 8014-8014.	1.6	1
267	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	1.4	1
268	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	1.4	1
269	Should we measure clonal circulating plasma cells in light chain amyloidosis?. Oncotarget, 2018, 9, 35607-35608.	1.8	1
270	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	1.4	1

#	Article	IF	CITATIONS
271	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	1.4	1
272	Patient-Reported Outcome Driven Case Management System for Hematology — a Prospective Study. Blood, 2018, 132, 719-719.	1.4	1
273	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. Blood, 2019, 134, 3171-3171.	1.4	1
274	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	1.4	1
275	Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy Journal of Clinical Oncology, 2020, 38, e20510-e20510.	1.6	1
276	Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs) Journal of Clinical Oncology, 2020, 38, e19112-e19112.	1.6	1
277	Disrupting the Reverse Warburg Effect As a Therapeutic Strategy in Multiple Myeloma. Blood, 2021, 138, 2649-2649.	1.4	1
278	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819.	1.4	1
279	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	1.4	1
280	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood, 2021, 138, 3774-3774.	1.4	1
281	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. Blood, 2021, 138, 3838-3838.	1.4	1
282	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	1.4	1
283	Sarcopenia identified by computed tomography (CT) imaging using a machine learning–based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM) Journal of Clinical Oncology, 2022, 40, 110-110.	1.6	1
284	A 49-Year-Old Woman With Acute Respiratory Failure. Chest, 2010, 138, 224-227.	0.8	0
285	Systemic amyloidosis masquerading as iron deficiency anemia. Indian Journal of Gastroenterology, 2012, 31, 351-352.	1.4	0
286	Bortezomib-based combination regimens in myeloma: more is not necessarily better. Leukemia and Lymphoma, 2014, 55, 1439-1440.	1.3	0
287	Secondary Hemophagocytic Syndrome Associated with Richter's Transformation in Chronic Lymphocytic Leukemia. Case Reports in Hematology, 2014, 2014, 1-4.	0.4	0
288	Drugs that affect blood coagulation, fibrinolysis, and hemostasis. Side Effects of Drugs Annual, 2014, 35, 617-631.	0.6	0

#	Article	IF	CITATIONS
289	Predictors of Survival in Multiple Myeloma Patients after Relapse from a Delayed Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, S137.	2.0	0
290	The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S239.	0.4	0
291	Clinical Features and Outcomes of Plasmacytoma: a National Cancer Database Study (2000 – 2011). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S81-S82.	0.4	0
292	Bortezomib Versus Non-Bortezomib Based Initial Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e140-e141.	0.4	0
293	Autologous Stem Cell Transplantation in Patients with AL Amyloidosis with Impaired Renal Function. Biology of Blood and Marrow Transplantation, 2019, 25, S389-S390.	2.0	0
294	Autologous Stem Cell Transplant for IgM Related AL Amyloidosis. Biology of Blood and Marrow Transplantation, 2019, 25, S388-S389.	2.0	0
295	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia Research, 2019, 87, 106264.	0.8	0
296	Clinically significant delay in engraftment with day -1 melphalan prior to stem cell infusion in myeloma patients receiving stem cell transplant Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e301-e302.	0.4	0
297	The Impact of Proliferating Polyclonal Plasma Cells on Outcome after Autologous Stem Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, S239.	2.0	0
298	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM) Journal of Clinical Oncology, 2021, 39, e20016-e20016.	1.6	0
299	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. Blood, 2013, 122, 754-754.	1.4	0
300	Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. Blood, 2013, 122, 2081-2081.	1.4	0
301	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. Blood, 2013, 122, 1842-1842.	1.4	0
302	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses. Blood, 2014, 124, 4780-4780.	1.4	0
303	Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients. Blood, 2014, 124, 4751-4751.	1.4	0
304	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. Blood, 2015, 126, 3297-3297.	1.4	0
305	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. Blood, 2015, 126, 4176-4176.	1.4	0
306	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. Blood, 2015, 126, 5303-5303.	1.4	0

#	Article	IF	CITATIONS
307	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. Blood, 2015, 126, 4370-4370.	1.4	0
308	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset Journal of Clinical Oncology, 2016, 34, 8035-8035.	1.6	0
309	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma Journal of Clinical Oncology, 2016, 34, 8053-8053.	1.6	0
310	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma Journal of Clinical Oncology, 2016, 34, 8017-8017.	1.6	0
311	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes Journal of Clinical Oncology, 2016, 34, 8062-8062.	1.6	0
312	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival Journal of Clinical Oncology, 2016, 34, 8016-8016.	1.6	0
313	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	1.4	0
314	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	1.4	0
315	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	1.4	0
316	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	1.4	0
317	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	1.4	0
318	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	1.4	0
319	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	1.4	0
320	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	1.4	0
321	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	1.4	0
322	Outcome of Very Young (≤40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. Blood, 2016, 128, 5576-5576.	1.4	0
323	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	1.4	0
324	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2016, 128, 2267-2267.	1.4	0

#	Article	IF	CITATIONS
325	The use of proteasome inhibitors among patients with POEMS syndrome Journal of Clinical Oncology, 2017, 35, e19530-e19530.	1.6	0
326	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL) Journal of Clinical Oncology, 2017, 35, 8049-8049.	1.6	0
327	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL) Journal of Clinical Oncology, 2017, 35, 8047-8047.	1.6	0
328	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition Journal of Clinical Oncology, 2017, 35, e19532-e19532.	1.6	0
329	Smoldering Waldenström's macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB) Journal of Clinical Oncology, 2017, 35, 1573-1573.	1.6	0
330	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma Journal of Clinical Oncology, 2017, 35, 8032-8032.	1.6	0
331	Treatment approaches and outcomes in extramedullary plasmacytomas Journal of Clinical Oncology, 2017, 35, 8050-8050.	1.6	0
332	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma Journal of Clinical Oncology, 2018, 36, 8023-8023.	1.6	0
333	Natural history of delp53 multiple myeloma Journal of Clinical Oncology, 2018, 36, e20017-e20017.	1.6	0
334	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM) Journal of Clinical Oncology, 2018, 36, 8045-8045.	1.6	0
335	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy Journal of Clinical Oncology, 2018, 36, 8030-8030.	1.6	0
336	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	1.4	0
337	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	1.4	0
338	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	1.4	0
339	Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. Blood, 2018, 132, 3182-3182.	1.4	0
340	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	1.4	0
341	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	1.4	0
342	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	1.4	0

#	Article	IF	CITATIONS
343	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	1.4	Ο
344	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	1.4	0
345	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	1.4	Ο
346	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	1.4	0
347	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	1.4	Ο
348	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	1.4	0
349	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	1.4	0
350	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	1.4	0
351	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. Blood, 2018, 132, 3436-3436.	1.4	Ο
352	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2018, 132, 4615-4615.	1.4	0
353	Plasmacytomas: many faces of one disease, or many diseases with one face?. Oncotarget, 2019, 10, 257-258.	1.8	Ο
354	Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved Journal of Clinical Oncology, 2019, 37, 8011-8011.	1.6	0
355	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity Journal of Clinical Oncology, 2019, 37, 8034-8034.	1.6	0
356	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. Blood, 2019, 134, 4505-4505.	1.4	0
357	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	1.4	Ο
358	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	1.4	0
359	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	1.4	0
360	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080.	1.4	0

#	Article	IF	CITATIONS
361	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833.	1.4	0
362	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. Blood, 2019, 134, 1904-1904.	1.4	0
363	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. Blood, 2019, 134, 5532-5532.	1.4	Ο
364	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197.	1.4	0
365	Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation Journal of Clinical Oncology, 2020, 38, e20506-e20506.	1.6	Ο
366	Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis Journal of Clinical Oncology, 2020, 38, 8516-8516.	1.6	0
367	Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels Journal of Clinical Oncology, 2020, 38, e20515-e20515.	1.6	Ο
368	Waiting in line for cancer treatments?. Gastrointestinal Cancer Research: GCR, 2011, 4, 147-9.	0.7	0
369	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. Blood, 2021, 138, 2707-2707.	1.4	Ο
370	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS). Blood, 2021, 138, 1333-1333.	1.4	0
371	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	1.4	Ο
372	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100. Blood, 2021, 138, 1617-1617.	1.4	0
373	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. Blood, 2021, 138, 3805-3805.	1.4	0
374	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	1.4	0
375	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	1.4	0
376	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	1.4	0
377	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	1.4	0
378	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	1.4	0

#	Article	IF	CITATIONS
379	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	1.4	0
380	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	1.4	0
381	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	1.4	0
382	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	1.4	0
383	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	1.4	0
384	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	1.4	0
385	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	1.4	0
386	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	1.4	0
387	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	1.4	0
388	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	1.4	0
389	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	1.4	0
390	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	1.4	0
391	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	2.4	0
392	Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing. Annals of Pharmacotherapy, 2023, 57, 29-35.	1.9	0
393	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice, 2022, , OP2100789.	2.9	0
394	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma Journal of Clinical Oncology, 2022, 40, e20001-e20001.	1.6	0